
The earnings season came to a close with Germany’s Merck doubling its first-quarter profits. For the week, drug trials, analyst …

Private biotech company MacroGenics has licenced its bi-specific antibody platform technology to Gilead Sciences for products aimed at four unnamed …
Eli Lilly and its partner MacroGenics have suspended phase III trials of their investigational type I diabetes drug Protege after …

